Genfit SA
XUP
Company Profile
Business description
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Contact
Parc Eurasante
885, Avenue Eugene Avinee
Loos59120
FRAT: +33 320164000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
180
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
With first timers at risk of poor investment decisions and an interest in speculative stocks, I explore my biggest investing mistake.
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
We see gross margin expansion on efficiencies and limited tariff impact
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.40 | 33.90 | 0.38% |
| CAC 40 | 7,762.23 | 65.22 | -0.83% |
| DAX 40 | 23,394.23 | 272.58 | -1.15% |
| Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
| FTSE 100 | 9,207.38 | 43.05 | -0.47% |
| HKSE | 26,484.68 | 33.97 | -0.13% |
| NASDAQ | 22,497.86 | 75.62 | -0.33% |
| Nikkei 225 | 45,754.93 | 124.62 | 0.27% |
| NZX 50 Index | 13,153.79 | 27.52 | -0.21% |
| S&P 500 | 6,637.97 | 18.95 | -0.28% |
| S&P/ASX 200 | 8,773.00 | 35.10 | 0.40% |
| SSE Composite Index | 3,853.30 | 0.34 | -0.01% |